Claim

1. A vaccine combination comprising

(i) a first composition comprising an immunologically effective amount of a recombinant adenovirus 26 (rAd26) adenovirus vector comprising a nucleic acid encoding an antigenic glycoprotein of a first filovirus subtype, wherein said first filovirus subtype is an Ebolavirus subtype, together with a pharmaceutically acceptable carrier; and

(ii) a second composition comprising an immunologically effective amount of a Modified Vaccinia Ankara (MVA) vector comprising a nucleic acid encoding an antigenic glycoprotein of an Ebolavirus subtype and additionally encoding at least one antigenic glycoprotein of another filovirus subtype, together with a pharmaceutically acceptable carrier;
wherein the first composition is to be used for priming said immune response and the second composition is to be used for boosting said immune response.

2. A vaccine combination according to claim 1, wherein the first composition (i) further comprises an adenovirus vector comprising a nucleic acid encoding an antigenic glycoprotein of a second filovirus subtype.

3. A vaccine combination according to claim 2, wherein the first composition (i) further comprises an adenovirus vector comprising a nucleic acid encoding an antigenic glycoprotein of a third filovirus subtype.

4. A vaccine combination according to claim 1, wherein the adenovirus vector in the first composition (i) comprises a nucleic acid encoding an antigenic glycoprotein with SEQ ID NO:1.

5. A vaccine combination according to claim 4, wherein composition (i) further comprises an adenovirus comprising a nucleic acid encoding an antigenic glycoprotein with SEQ ID NO:2.

6. A vaccine combination according to claim 5, wherein composition (i) further comprises an adenovirus comprising a nucleic acid encoding an antigenic glycoprotein with SEQ

ID NO:3.

7. A vaccine combination according to any one of claims 1-6, wherein the MVA vector in composition (ii) comprises a nucleic acid encoding antigenic glycoproteins of at least four filovirus subtypes.

8. A vaccine combination according to any one of claims 1-7, wherein the MVA vector in composition (ii) comprises a nucleic acid encoding antigenic glycoproteins from four different filovirus subtypes having SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 5.

9. A vaccine combination according to any one of claims 1-8 for use in generating a protective immune response against at least one filovirus subtype, wherein the first composition is to be used for priming said immune response and the second composition is to be used for boosting said immune response.

10. A vaccine combination according to any one of claims 1-8 for use in the preparation of a pharmaceutical composition or medicament.

11. A kit comprising the vaccine combination according to any one of claims 1-8, wherein the first composition is to be used for priming said immune response and the second composition is to be used for boosting said immune response.

12. Use of a first composition comprising an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding an antigenic glycoprotein of a first filovirus subtype, wherein the first filovirus subtype is an Ebolavirus subtype, together with a pharmaceutically acceptable carrier; and a second composition comprising an immunologically effective amount of an MVA vector comprising a nucleic acid encoding antigenic glycoproteins of at least two filovirus subtypes, wherein the at least two filovirus subtypes are Ebolavirus subtypes, together with a pharmaceutically acceptable carrier; each in the manufacture of a

medicament for the combined treatment of a filovirus infection, wherein the first composition is a priming composition and the second composition is a boosting composition.